Nalbuphine ER: Phase II/III started

Trevi began a double-blind, placebo-controlled, international Phase II/III trial to evaluate 90 and 180 mg oral Nalbuphine ER twice daily for 8 weeks in about 60 patients with moderate to severe itch....